SCHEMBL416779

SCHEMBL416779

COC(=O)c1cc(Cl)ccc1NC(=O)c1ccc(-c2cccs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
KDM4E B2RXH2 3/20 0.57
MEN1 O00255 1/20 0.57
ALDH1A1 P00352 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPT P10636 3/20 0.56
SERPINE1 P05121 4/20 0.54
HDAC1 Q13547 7/20 0.53
HDAC2 Q92769 4/20 0.53
HDAC3 O15379 3/20 0.53
HDAC4 P56524 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
THRB P10828 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415896 0.87 SERPINE1 (0.71) KDM4ESERPINE1HDAC1HDAC2HDAC3
SCHEMBL14082877 0.83 KDM4E (0.67) KMT2AKDM4EMEN1ALDH1A1L3MBTL1
SCHEMBL417476 0.80 SERPINE1 (0.56) KMT2AKDM4EMEN1ALDH1A1MAPT
SCHEMBL14082981 0.79 MEN1 (0.50) KMT2AKDM4EMEN1ALDH1A1L3MBTL1
SCHEMBL12369425 0.78 HDAC1 (0.67) KMT2AKDM4EMEN1ALDH1A1L3MBTL1
SCHEMBL1016195 0.78 KDM4E (0.46) KMT2AKDM4EMEN1ALDH1A1L3MBTL1
SCHEMBL417055 0.77 SERPINE1 (0.80) KMT2AKDM4EMEN1ALDH1A1L3MBTL1
SCHEMBL420185 0.77 SERPINE1 (0.77) KDM4EALDH1A1MAPTSERPINE1HSD17B10
SCHEMBL20850165 0.77 MAPT (0.53) KMT2AKDM4EMEN1L3MBTL1MAPT
SCHEMBL421465 0.76 SERPINE1 (0.65) KMT2AKDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 KMT2A 4433/4885KDM4E 4490/4885MEN1 844/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KMT2A 4433/4885KDM4E 4490/4885MEN1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.